20744-39-2, In homogeneous catalysis, the catalyst is in the same phase as the reactant. The number of collisions between reactants and catalyst is at a maximum.In a patent, 20744-39-2, name is Pyridazin-4-amine, introducing its new discovery.
NOVEL COMPOUNDS
The present invention discloses novel compounds inhibiting LRRK2 kinase activity, the preparation processes thereof, the compositions containing them, as well as the use in treating diseases characterized by LRRK2 kinase activity, particularly Parkinson?s disease and Alzheimer?s disease
Note that a catalyst decreases the activation energy for both the forward and the reverse reactions and hence accelerates both the forward and the reverse reactions.20744-39-2, you can also check out more blogs about20744-39-2
Reference£º
Pyridazine – Wikipedia,
Pyridazine | C4H4N131 – PubChem